Bioton, Poland, prepares for an IPO
Bioton, a Polish biotech company specialising in the production of recombinant insulin will be hoping to generate more funds from an IPO scheduled for later this year. The prospectus is expected to be available this month.
The company produces Gensulin, a sythetic horome, which is already on sale in some parts of the world and is expected to be registered in Europe in 2-3 yrs time.
This is taken from an original article in the Warsaw Business Journal. Read the whole article here.
Visit the Bioton website here.
ScanBalt News
19 February 2025
Unlocking Opportunities: Latest Trends & Developments in Sweden’s Life Sciences & Health Sectors | 7 March 2025, 10:00-11:00 CET (online)
18 October 2024
Unlocking Europe's Potential in Bioproduction | 12 November 2024 | 10:30-12:00 CET (online)
10 October 2024
NOME Startup Competition 2024 | Dealine November 1st